Pignon JP, le Maitre A, Maillard E, Bourhis J, Group M-NC. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2009;92(1):4–14. https://doi.org/10.1016/j.radonc.2009.04.014.
Y Pointreau I Atean J Fayette G Calais JL Lefebvre 2011 Induction chemotherapy in head and neck cancer: a new paradigm Anticancer Drugs 22 7 613 620 https://doi.org/10.1097/CAD.0b013e3283425871
GN Marta WN William Jr O Feher AL Carvalho LP Kowalski 2015 Induction chemotherapy for oral cavity cancer patients: Current status and future perspectives Oral Oncol 51 12 1069 1075 https://doi.org/10.1016/j.oraloncology.2015.10.009
SM Gore AK Crombie MD Batstone JR Clark 2015 Concurrent chemoradiotherapy compared with surgery and adjuvant radiotherapy for oral cavity squamous cell carcinoma Head Neck 37 4 518 523 https://doi.org/10.1002/hed.23626
NG Iyer DS Tan VK Tan W Wang J Hwang NC Tan 2015 Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis Cancer 121 10 1599 1607 https://doi.org/10.1002/cncr.29251
L Licitra C Grandi M Guzzo L Mariani S Lo Vullo F Valvo 2003 Primary chemotherapy in resectable oral cavity squamous cell cancer: a randomized controlled trial Journal of clinical oncology : official journal of the American Society of Clinical Oncology 21 2 327 333
P Bossi S Lo Vullo M Guzzo L Mariani R Granata E Orlandi 2014 Preoperative chemotherapy in advanced resectable OCSCC: long-term results of a randomized phase III trial Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 25 2 462 466 https://doi.org/10.1093/annonc/mdt555
LP Zhong CP Zhang GX Ren W Guo WN William Jr J Sun 2013 Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma Journal of clinical oncology : official journal of the American Society of Clinical Oncology 31 6 744 751 https://doi.org/10.1200/JCO.2012.43.8820
LP Zhong CP Zhang GX Ren W Guo WN William Jr CS Hong 2015 Long-term results of a randomized phase III trial of TPF induction chemotherapy followed by surgery and radiation in locally advanced oral squamous cell carcinoma Oncotarget 6 21 18707 18714 https://doi.org/10.18632/oncotarget.4531
GN Marta R Riera P Bossi LP Zhong L Licitra CR Macedo 2015 Induction chemotherapy prior to surgery with or without postoperative radiotherapy for oral cavity cancer patients: systematic review and meta-analysis Eur J Cancer https://doi.org/10.1016/j.ejca.2015.08.007
Inductive toripalimab and paclitaxel/cisplatin on pathological response in oral squamous cell carcinoma patients. https://ClinicalTrials.gov/show/NCT04473716 Accessed 08 February 2021.
A Phase II trial of TPF induction chemotherapy in cN2 OSCC patients. https://ClinicalTrials.gov/show/NCT02285543 Accessed 08 February 2021.
Carboplatin, nab-paclitaxel, durvalumab before surgery and adjuvant therapy in head and neck squamous cell carcinoma. https://ClinicalTrials.gov/show/NCT03174275 Accessed 08 February 2021.
Neoadjuvant sintilimab in combination with carboplatin and nab-paclitaxel in untreated oral cavity squamous cell carcinoma. https://ClinicalTrials.gov/show/NCT04718415 Accessed 08 February 2021.
R Hitt A López-Pousa J Martínez-Trufero V Escrig J Carles A Rizo 2005 Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer J Clin Oncol 23 34 8636 8645 https://doi.org/10.1200/jco.2004.00.1990
MR Posner DM Hershock CR Blajman E Mickiewicz E Winquist V Gorbounova 2007 Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer N Engl J Med 357 17 1705 1715 https://doi.org/10.1056/NEJMoa070956
JH Lorch O Goloubeva RI Haddad K Cullen N Sarlis R Tishler 2011 Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial Lancet Oncol 12 2 153 159 https://doi.org/10.1016/s1470-2045(10)70279-5
JB Vermorken E Remenar C Herpen van T Gorlia R Mesia M Degardin 2007 Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer N Engl J Med 357 17 1695 1704 https://doi.org/10.1056/NEJMoa071028
Vermorken JB, Remenar E, Herpen CV, Degardin M, Stewart JS, Gurunath RK, et al. Long-term results from EORTC24971/TAX323: comparing TPF to PF in patients with unresectable squamous cell carcinoma of the head and neck (SCCHN). Journal of Clinical Oncology. 2011;29(15_suppl):5530-. doi: https://doi.org/10.1200/jco.2011.29.15_suppl.5530.
P Blanchard J Bourhis B Lacas MR Posner JB Vermorken JJ Cruz Hernandez 2013 Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group J Clin Oncol 31 23 2854 2860 https://doi.org/10.1200/jco.2012.47.7802
R Haddad A O'Neill G Rabinowits R Tishler F Khuri D Adkins 2013 Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial Lancet Oncol 14 3 257 264 https://doi.org/10.1016/s1470-2045(13)70011-1
EE Cohen TG Karrison M Kocherginsky J Mueller R Egan CH Huang 2014 Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer J Clin Oncol 32 25 2735 2743 https://doi.org/10.1200/jco.2013.54.6309
R Hitt JJ Grau A López-Pousa A Berrocal C García-Girón A Irigoyen 2014 A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer Ann Oncol 25 1 216 225 https://doi.org/10.1093/annonc/mdt461
MG Ghi A Paccagnella D Ferrari P Foa D Alterio C Codeca 2017 Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer A phase II-III trial Ann Oncol 28 9 2206 2212 https://doi.org/10.1093/annonc/mdx299
W Budach E Bölke K Kammers PA Gerber K Orth S Gripp 2016 Induction chemotherapy followed by concurrent radio-chemotherapy versus concurrent radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck (HNSCC): a meta-analysis of randomized trials Radiother Oncol 118 2 238 243 https://doi.org/10.1016/j.radonc.2015.10.014
JP Machiels C René Leemans W Golusinski C Grau L Licitra V Gregoire 2020 Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 31 11 1462 1475 https://doi.org/10.1016/j.annonc.2020.07.011This clinical practice guideline summarizes the current standard of care treatment for locally advanced head and neck squamous cell carcinoma, including advanced oral cavity cancer.
National Comprehensive Cancer Network. Head and Neck Cancer (Version 01.2021). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf (2021). Accessed January 8th 2021.
VM Patil K Prabhash V Noronha A Joshi V Muddu S Dhumal 2014 Neoadjuvant chemotherapy followed by surgery in very locally advanced technically unresectable oral cavity cancers Oral Oncol 50 10 1000 1004 https://doi.org/10.1016/j.oraloncology.2014.07.015
R Alzahrani A Obaid H Al-Hakami A Alshehri H Al-Assaf R Adas 2020 Locally advanced oral cavity cancers: what is the optimal care? Cancer Control 27 1 1073274820920727 https://doi.org/10.1177/1073274820920727
AH Rudresha T Chaudhuri KC Lakshmaiah KG Babu L Dasappa LA Jacob 2017 Induction chemotherapy in locally advanced T4b oral cavity squamous cell cancers: a regional cancer center experience Indian J Cancer 54 1 35 38 https://doi.org/10.4103/ijc.IJC_131_17
A Joshi VM Patil V Noronha S Juvekar A Deshmukh P Chatturvedi 2013 Is there a role of induction chemotherapy followed by resection in T4b oral cavity cancers? Indian J Cancer 50 4 349 355 https://doi.org/10.4103/0019-509x.123627
AH Rudresha T Chaudhuri KC Lakshmaiah KG Babu L Dasappa LA Jacob 2017 Induction chemotherapy in technically unresectable locally advanced t4a oral cavity squamous cell cancers: experience from a regional cancer center of South India Indian J Med Paediatr Oncol 38 4 490 494 https://doi.org/10.4103/ijmpo.ijmpo_185_16
VM Patil V Noronha A Joshi VK Muddu S Gulia B Bhosale 2013 Induction chemotherapy in technically unresectable locally advanced oral cavity cancers: does it make a difference? Indian J Cancer 50 1 1 8 https://doi.org/10.4103/0019-509x.112263
V Noronha V Patil A Joshi V Muddu A Bhattacharjee S Juvekar 2015 Is taxane/platinum/5 fluorouracil superior to taxane/platinum alone and does docetaxel trump paclitaxel in induction therapy for locally advanced oral cavity cancers? Indian J Cancer 52 1 70 73 https://doi.org/10.4103/0019-509x.175604
Burtness B, Harrington KJ, Greil R, Soulieres D, Tahara M, de Castro G, Jr., et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394(10212):1915-28. https://doi.org/10.1016/s0140-6736(19)32591-7 (This prospective phase III trial supported the use of immunotherapy in the first-line treatment of recurrent metastatic head and neck cancer and reinforces the rational for incorporating immunotherapy in the curative setting.)
RL Ferris G Blumenschein Jr J Fayette J Guigay AD Colevas L Licitra 2018 Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression Oral Oncol 81 45 51 https://doi.org/10.1016/j.oraloncology.2018.04.008
RL Ferris G Blumenschein Jr J Fayette J Guigay AD Colevas L Licitra 2016 Nivolumab for recurrent squamous-cell carcinoma of the head and neck N Engl J Med 375 19 1856 1867 https://doi.org/10.1056/NEJMoa1602252
R Uppaluri KM Campbell AM Egloff P Zolkind ZL Skidmore B Nussenbaum 2020 Neoadjuvant and adjuvant pembrolizumab in resectable locally advanced, human papillomavirus-unrelated head and neck cancer: a multicenter, phase II trial Clin Cancer Res 26 19 5140 5152 https://doi.org/10.1158/1078-0432.Ccr-20-1695This window of opportunity prospective phase II trial shows evidence of major pathologic response to neoadjuvant pembrolizumab in resectable locally advanced head and neck cancer, suggesting a potential benefit of incorporating immunotherapy in this setting.
JD Schoenfeld GJ Hanna VY Jo B Rawal YH Chen PS Catalano 2020 Neoadjuvant nivolumab or nivolumab plus ipilimumab in untreated oral cavity squamous cell carcinoma: a phase 2 open-label randomized clinical trial JAMA Oncol 6 10 1563 1570 https://doi.org/10.1001/jamaoncol.2020.2955Another window of opportunity trial showing evidence of major pathologic response and suggesting a potential benefit of incorporating immunotherapy in the neoadjuvant setting.
CA209-891: neoadjuvant and adjuvant nivolumab as immune checkpoint inhibition in oral cavity cancer. https://ClinicalTrials.gov/show/NCT03721757 Accessed 08 February 2021.
Neoadjuvant PD-1 blockade in resectable oral squamous cell carcinoma. https://ClinicalTrials.gov/show/NCT04649476 Accessed 08 February 2021.
Neoadjuvant anti-PD-1 antibody (toripalimab) or combined with chemotherapy in HNSCC patients.: https://ClinicalTrials.gov/show/NCT04164238 Accessed 08 February 2021.
Neoadjuvant nivolumab for oral cancer combined with FDG and anti-PD-L1 PET/CT Imaging for response prediction. https://ClinicalTrials.gov/show/NCT03843515 Accessed 08 February 2021.
Trial of nivolumab as a novel neoadjuvant pre-surgical therapy for locally advanced oral cavity cancer. https://ClinicalTrials.gov/show/NCT03021993 Accessed 08 February 2021.
Study of pembrolizumab given prior to surgery and in combination with radiotherapy given post-surgery for advanced head and neck squamous cell carcinoma (MK-3475-689). https://ClinicalTrials.gov/show/NCT03765918 Accessed 08 February 2021.
Preoperative immunotherapy in patients with squamous cell carcinoma of the head and neck. https://ClinicalTrials.gov/show/NCT03708224 Accessed 08 February 2021.
L Geoffrois L Martin D Raucourt De XS Sun Y Tao P Maingon 2018 Induction Chemotherapy followed by cetuximab radiotherapy is not superior to concurrent chemoradiotherapy for head and neck carcinomas: results of the GORTEC 2007–02 phase III randomized trial J Clin Oncol 36 31 3077 3083 https://doi.org/10.1200/jco.2017.76.2591